The FDA's new pathway for rare disease drugs, based on causal biology, is scientifically promising. However, the name "plausible mechanism" is a critical flaw. The term sounds weak, creating doubt for patients and giving payers powerful leverage to deny coverage by implying a lower standard of evidence.

Drug developers often operate under a hyper-conservative perception of FDA requirements, avoiding novel approaches even when regulators might encourage them. This anticipatory compliance, driven by risk aversion, becomes a greater constraint than the regulations themselves, slowing down innovation and increasing costs.

The FDA receives raw and cleaned datasets from sponsors, not just summary reports. Their internal teams conduct independent analyses, which can lead to findings or data presentations in the official drug label that differ from or expand upon what's in the published paper.

To find a single viable drug name, agencies like Brand Institute generate an initial list of 300 to 500 concepts. This massive brainstorming effort highlights the scale of the creative process, with the vast majority of ideas being rejected long before regulatory review.

The 1988 launch of Prozac marked a major shift in pharmaceutical branding. Its name was a non-descriptive "empty vessel" designed for marketing impact ('pro' for positive, 'zac' for energy), moving away from names that explained a drug's function.

The FDA defines a peptide as an amino acid chain of 40 or less. Blockbuster drugs like Ozempic and Mounjaro are all exactly 39 amino acids long. This perfect fit suggests potential regulatory shaping or clever drug design to fit an advantageous classification.

Recent conspiracy theories blame the WHO for suppressing cancer cures. However, the WHO has no drug approval authority in the US. The FDA is the sole regulator, making it the more logical focus for scrutiny and reform advocacy regarding healthcare innovation.

To prevent errors from illegible handwriting, the FDA favors drug names with a varied visual shape, created by using letters that ascend (b, d, h) and descend (g, p, y). This typographical safety consideration is a key, non-obvious factor in a name's approval.

Unlike consumer-facing drugs, many cancer therapies have names derived from their scientific mechanism of action. This is a deliberate strategy to communicate the drug's uniqueness and resonate with the true target audience: oncologists who understand the science.